Assessment of Herpes Zoster Risk Among Recipients of COVID-19 Vaccine.
Assessment of Herpes Zoster Risk Among Recipients of COVID-19 Vaccine.
复制标题
DOI：
10.1001/jamanetworkopen.2022.42240
复制
发表时间：
2022-11-01
影响因子：
13.8
通讯作者：
Acharya, Nisha R.
中科院分区：
文献类型：
--
作者：
Akpandak, Idara;Miller, D. Claire;Sun, Yuwei;Arnold, Benjamin F.;Kelly, J. Daniel;Acharya, Nisha R.
接种COVID-19疫苗后带状疱疹感染的风险是否会增加？在这项队列研究中，2 039 854名接种COVID-19疫苗的个体被纳入美国医疗保健索赔数据库，自我对照风险区间分析显示，COVID-19疫苗接种后带状疱疹的发病率比为0.91。一项补充队列分析发现，与大流行前和大流行早期的流感疫苗接种相比，接种COVID-19疫苗后带状疱疹的风险没有增加。这些发现表明，COVID-19疫苗接种与带状疱疹风险增加无关，这可能有助于解决对COVID-19疫苗安全性的担忧。许多病例研究报告了COVID-19疫苗接种后的带状疱疹感染。目前尚不清楚这些病例是否代表报告增加或真正的风险增加。评估COVID-19疫苗接种是否与带状疱疹感染风险增加相关。这项队列研究采用自我对照风险间隔（SCRI）设计，比较了COVID-19疫苗接种后30天或直至第二剂疫苗接种日期的风险间隔内带状疱疹的风险，以及远离COVID-19疫苗接种的对照间隔（定义为每个个体最后一次记录的疫苗接种日期后60-90天，允许控制和风险间隔之间有30天的洗脱期）。使用补充队列分析来比较在大流行前时期（2018年1月1日至2019年12月31日）或大流行早期（2020年3月1日至2020年11月30日）接种流感疫苗的2个历史队列中接种COVID-19疫苗后带状疱疹的风险与流感疫苗接种后带状疱疹的风险。数据来自Optum Labs Data Warehouse，这是一个基于美国国家去识别索赔的数据库。2020年12月11日至2021年6月30日期间，共有2 039 854名获得紧急使用许可的COVID-19疫苗（BNT 162 b2 [Pfizer-BioNTech]、mRNA-1273 [Moderna]或Ad26.COV2.S [约翰逊&约翰逊]）接种者符合入选条件。SCRI分析中包括的个人是在风险或控制间隔期间患有带状疱疹的COVID-19疫苗接种队列的一个子集。任何剂量的COVID-19疫苗。带状疱疹事件，根据疾病和相关健康问题国际统计分类第十版编码定义，并在诊断后5天内开具新的抗病毒药物处方或增加抗病毒药物剂量。在研究期间接受任何剂量COVID-19疫苗的2 039 854人中，平均（SD）年龄为43.2（16.3）岁; 1 031 149人（50.6%）为女性，1 344 318人（65.9%）为白色。其中，1451例诊断为带状疱疹的患者（平均[SD]年龄，51.6 [12.6]岁; 845例[58.2%]女性）被纳入主要SCRI分析。在SCRI分析中，调整后COVID-19疫苗接种与带状疱疹风险增加无关（发病率比，0.91; 95%CI，0.82-1.01; P = 0.08）。在补充队列分析中，与大流行前时期的流感疫苗接种相比，COVID-19疫苗接种与带状疱疹风险升高无关（第一剂COVID-19疫苗：风险比[HR]，0.78 [95% CI，0.70-0.86; P < .001];第二剂COVID-19疫苗：HR，0.79 [95% CI，0.71-0.88; P < .001]）或大流行早期（COVID-19疫苗第一剂：HR，0.89 [95% CI，0.80-1.00; P = .05];第二剂：HR，0.91 [95% CI，0.81-1.02; P = .09]）。在这项研究中，未发现COVID-19疫苗接种与带状疱疹感染风险增加之间存在关联，这可能有助于解决患者和临床医生对COVID-19疫苗安全性的担忧。这项队列研究使用美国国家索赔数据库的数据来评估COVID-19疫苗接种是否与带状疱疹感染相关。
Is there an increased risk of herpes zoster infection after COVID-19 vaccination? In this cohort study of 2 039 854 individuals who received a COVID-19 vaccine included in a US health care claims database, a self-controlled risk interval analysis revealed that the incidence rate ratio of herpes zoster after COVID-19 vaccination was 0.91. A supplementary cohort analysis found no increased risk of herpes zoster after COVID-19 vaccination compared with influenza vaccination in the prepandemic and early pandemic period. These findings suggest COVID-19 vaccination is not associated with an increased risk of herpes zoster, which may help to address concerns about the safety profile of COVID-19 vaccines. Herpes zoster infection after COVID-19 vaccination has been reported in numerous case studies. It is not known whether these cases represent increased reporting or a true increase in risk. To assess whether COVID-19 vaccination is associated with an increased risk of herpes zoster infection. This cohort study used a self-controlled risk interval (SCRI) design to compare the risk of herpes zoster in a risk interval of 30 days after COVID-19 vaccination or up to the date of the second vaccine dose with a control interval remote from COVID-19 vaccination (defined as 60-90 days after the last recorded vaccination date for each individual, allowing for a 30-day washout period between control and risk intervals). A supplemental cohort analysis was used to compare the risk of herpes zoster after COVID-19 vaccination with the risk of herpes zoster after influenza vaccination among 2 historical cohorts who received an influenza vaccine in the prepandemic period (January 1, 2018, to December 31, 2019) or the early pandemic period (March 1, 2020, to November 30, 2020). Data were obtained from Optum Labs Data Warehouse, a US national deidentified claims-based database. A total of 2 039 854 individuals who received any dose of a COVID-19 vaccine with emergency use authorization (BNT162b2 [Pfizer-BioNTech], mRNA-1273 [Moderna], or Ad26.COV2.S [Johnson & Johnson]) from December 11, 2020, through June 30, 2021, were eligible for inclusion. Individuals included in the SCRI analysis were a subset of the COVID-19–vaccinated cohort who had herpes zoster during either a risk or control interval. Any dose of a COVID-19 vaccine. Incident herpes zoster, defined by International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes and a prescription of a new antiviral medication or a dose increase in antiviral medication within 5 days of diagnosis. Among 2 039 854 individuals who received any dose of a COVID-19 vaccine during the study period, the mean (SD) age was 43.2 (16.3) years; 1 031 149 individuals (50.6%) were female, and 1 344 318 (65.9%) were White. Of those, 1451 patients (mean [SD] age, 51.6 [12.6] years; 845 [58.2%] female) with a herpes zoster diagnosis were included in the primary SCRI analysis. In the SCRI analysis, COVID-19 vaccination was not associated with an increased risk of herpes zoster after adjustment (incidence rate ratio, 0.91; 95% CI, 0.82-1.01; P = .08). In the supplementary cohort analysis, COVID-19 vaccination was not associated with a higher risk of herpes zoster compared with influenza vaccination in the prepandemic period (first dose of COVID-19 vaccine: hazard ratio [HR], 0.78 [95% CI, 0.70-0.86; P < .001]; second dose of COVID-19 vaccine: HR, 0.79 [95% CI, 0.71-0.88; P < .001]) or the early pandemic period (first dose of COVID-19 vaccine: HR, 0.89 [95% CI, 0.80-1.00; P = .05]; second dose: HR, 0.91 [95% CI, 0.81-1.02; P = .09]). In this study, there was no association found between COVID-19 vaccination and an increased risk of herpes zoster infection, which may help to address concerns about the safety profile of the COVID-19 vaccines among patients and clinicians. This cohort study uses data from a US national claims database to assess whether COVID-19 vaccination is associated with herpes zoster infection.
登录
查看更多内容
影响因子：
5.5
作者：
Brosh-Nissimov T;Sorek N;Yeshayahu M;Zherebovich I;Elmaliach M;Cahan A;Amit S;Rotlevi E
通讯作者：
Rotlevi E
DOI：
10.1111/jdv.18184
发表时间：
2022-08
影响因子：
9.2
作者：
Hertel, M.;Heiland, M.;Nahles, S.;von Laffert, M.;Mura, C.;Bourne, P. E.;Preissner, R.;Preissner, S.
通讯作者：
Preissner, S.
影响因子：
5
作者：
Baker, Meghan A.;Lieu, Tracy A.;Nguyen, Michael D.
通讯作者：
Nguyen, Michael D.
影响因子：
168.9
作者：
Walter, R;Hartmann, K;Kuhn, M
通讯作者：
Kuhn, M
影响因子：
--
作者：
Rodríguez-Jiménez P;Chicharro P;Cabrera LM;Seguí M;Morales-Caballero Á;Llamas-Velasco M;Sánchez-Pérez J
通讯作者：
Sánchez-Pérez J